Pre-Made Tengonermin Biosimilar, Fusion Protein targeting ANPEP fused with human TNF (tumor necrosis factor (TNF) superfamily member 2, TNFSF2, TNF-alpha, TNFA): Recombinant therapeutic protein targeting APN/CD13/GP150/LAP1/P150/PEPN for drug discovery and mechanism of action (MOA) research

Pre-Made Tengonermin Biosimilar, Fusion Protein targeting ANPEP fused with human TNF (tumor necrosis factor (TNF) superfamily member 2, TNFSF2, TNF-alpha, TNFA): Recombinant therapeutic protein targeting APN/CD13/GP150/LAP1/P150/PEPN is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.

Tengonermin, also known as NGR-hTNF, is a vascular-targeting drug.  It is a recombinant protein coupling the N-terminus of hTNF-α with the C-terminus of a tumour-homing NGR-peptide, which is a ligand of the aminopeptidase N (CD13) overexpressed by endothelial cells of newly formed human tumour blood vessels. Tengonermin modify the tumor microenvironment and increase intra-tumoral chemotherapy penetration and T-cell infiltration.

Order information

* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry

Catalog No.	Package	Price(In USD)	Qty (Quantity)	Sum(In USD)
GMP-Bios-INN-1020-1mg	1mg	3090
GMP-Bios-INN-1020-10mg	10mg	Inquiry
GMP-Bios-INN-1020-100mg	100mg	Inquiry
GMP-Bios-INN-1020-xmg	≥100mg	Inquiry
			Shipping Cost:	760.00
			Total:

Description

Products Name (INN Index)	Pre-Made Tengonermin Biosimilar, Fusion Protein targeting ANPEP fused with human TNF (tumor necrosis factor (TNF) superfamily member 2, TNFSF2, TNF-alpha, TNFA): Recombinant therapeutic protein targeting APN/CD13/GP150/LAP1/P150/PEPN
INN Name	Tengonermin
Target	ANPEP
Format	Fusion Protein
Derivation	human
Species Reactivity	human
CH1 Isotype	Fusion - [NGR peptide 1-6 - TNF (tumor necrosis factor (TNF) superfamily member 2, TNFSF2, TNF- alpha, TNFA)] - trimer
VD LC	Fusion - [NGR peptide 1-6 - TNF (tumor necrosis factor (TNF) superfamily member 2, TNFSF2, TNF- alpha, TNFA)] - trimer
Highest_Clin_Trial (Jan '20)
Est. Status
100% SI Structure
99% SI Structure
95-98% SI Structure
Year Proposed
Year Recommended
Companies	MolMed SpA (Milano Italy)
Conditions Approved
Conditions Active
Conditions Discontinued
Development Tech	0